Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

245
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
245
Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

10.8K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
10.8K
Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

630
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
630
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

305
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
305
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

390
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
390
Serum Studies: Renal Function Tests01:24

Serum Studies: Renal Function Tests

548
Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
548

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiomics prediction and immunogenic validation of personalized neoantigens in cholangiocarcinoma patients.

Journal of translational medicine·2026
Same author

Mitigating Intraoperative Fatigue in Surgeons at High Altitude: A Stepped-Wedge Cluster Randomized Trial.

High altitude medicine & biology·2026
Same author

Minimizing Implant Rejections through Low-Inflammatory and Immune-Regulatory Biointerfaces.

ACS applied materials & interfaces·2026
Same author

Wandering spleen.

Hepatobiliary surgery and nutrition·2026
Same author

Rethinking nutritional risk in cancer: muscle quality, myosteatosis, and prognosis.

Hepatobiliary surgery and nutrition·2026
Same author

Efficacy and safety of drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy in unresectable gastric cancer with liver metastasis.

Therapeutic advances in medical oncology·2026

Related Experiment Video

Updated: Mar 8, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

11.2K

Albumin Binding Function: The Potential Earliest Indicator for Liver Function Damage.

Penglei Ge1, Huayu Yang1, Jingfen Lu2

  • 1Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and PUMC, Beijing, China.

Gastroenterology Research and Practice
|January 20, 2017
PubMed
Summary
This summary is machine-generated.

New indicators, albumin metal ion and fatty acid binding capacities, show promise for early detection of liver diseases like viral hepatitis and NAFLD before conventional biomarkers change.

More Related Videos

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube
06:12

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube

Published on: April 28, 2020

12.1K
Assessment of Kidney Function in Mouse Models of Glomerular Disease
09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

18.7K

Related Experiment Videos

Last Updated: Mar 8, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

11.2K
Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube
06:12

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube

Published on: April 28, 2020

12.1K
Assessment of Kidney Function in Mouse Models of Glomerular Disease
09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

18.7K

Area of Science:

  • Hepatology
  • Biochemistry
  • Clinical Diagnostics

Background:

  • Current biomarkers lack sensitivity for early liver disease detection.
  • Early stages of viral hepatitis, NAFLD, and cirrhosis require better diagnostic indicators.
  • Albumin's binding functions are explored as potential novel markers.

Purpose of the Study:

  • To investigate if albumin binding function reflects liver function in early liver diseases.
  • To assess metal ion and fatty acid binding capacities of albumin.
  • To compare these capacities with conventional liver enzymes.

Main Methods:

  • Observational study of 193 patients with NAFLD, viral hepatitis, and cirrhosis.
  • Measurement of Ischemia-Modified Albumin (IMAT) and Total Binding Sites (TBS).
  • Analysis of albumin binding capacities in relation to Child-Pugh score in cirrhosis patients.

Main Results:

  • IMAT and TBS significantly decreased in NAFLD and early hepatitis patients.
  • Albumin binding capacities declined before liver enzyme alterations in hepatitis.
  • IMAT levels varied with cirrhosis severity (Child-Pugh A, B, C).

Conclusions:

  • Albumin metal ion and fatty acid binding capacities change early in liver disease.
  • These capacities may serve as sensitive indicators for early liver function evaluation.
  • This study identifies potential novel biomarkers for liver damage.